Get started
Protagonist Therapeutics, Inc.Protagonist Therapeutics, Inc.Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

PTGX chart


Full chart

PTGX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.62 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
10.13
Basic EPS (TTM)
4.48 USD
Net income (FY)
‪275.19 M‬ USD
Revenue (FY)
‪434.43 M‬ USD
Shares float
‪57.88 M‬
Beta (1Y)
0.62

Employees


Employees (FY)
126
Change (1Y)
+14 +12.50%
Revenue / Employee (1Y)
‪3.45 M‬ USD
Net income / Employee (1Y)
‪2.18 M‬ USD

About Protagonist Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Dinesh V. Patel
Website
protagonist-inc.com
Headquarters
Newark
Founded
2006
FIGI
BBG002B63KM7
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

PTGX news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as PTGX.

Frequently Asked Questions


The current price of PTGX is 46.85 USD — it has increased by 5.65% in the past 24 hours. Watch Protagonist Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Protagonist Therapeutics, Inc. stocks are traded under the ticker PTGX.
PTGX stock has risen by 3.71% compared to the previous week, the month change is a −18.13% fall, over the last year Protagonist Therapeutics, Inc. has showed a 72.37% increase.
We've gathered analysts' opinions on Protagonist Therapeutics, Inc. future price: according to them, PTGX price has a max estimate of 82.00 USD and a min estimate of 45.00 USD. Watch PTGX chart and read a more detailed Protagonist Therapeutics, Inc. stock forecast: see what analysts think of Protagonist Therapeutics, Inc. and suggest that you do with its stocks.
PTGX reached its all-time high on Mar 12, 2025 with the price of 60.60 USD, and its all-time low was 4.47 USD and was reached on Dec 3, 2019. View more price dynamics on PTGX chart.
See other stocks reaching their highest and lowest prices.
PTGX stock is 7.45% volatile and has beta coefficient of 0.62. Track Protagonist Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Protagonist Therapeutics, Inc. there?
Today Protagonist Therapeutics, Inc. has the market capitalization of ‪2.76 B‬, it has decreased by −7.83% over the last week.
Yes, you can track Protagonist Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Protagonist Therapeutics, Inc. is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
PTGX earnings for the last quarter are 1.98 USD per share, whereas the estimation was 1.39 USD resulting in a 42.60% surprise. The estimated earnings for the next quarter are −0.06 USD per share. See more details about Protagonist Therapeutics, Inc. earnings.
Protagonist Therapeutics, Inc. revenue for the last quarter amounts to ‪170.64 M‬ USD, despite the estimated figure of ‪132.36 M‬ USD. In the next quarter, revenue is expected to reach ‪37.50 M‬ USD.
PTGX net income for the last quarter is ‪131.67 M‬ USD, while the quarter before that showed ‪−33.21 M‬ USD of net income which accounts for 496.49% change. Track more Protagonist Therapeutics, Inc. financial stats to get the full picture.
No, PTGX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 126 employees. See our rating of the largest employees — is Protagonist Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Protagonist Therapeutics, Inc. EBITDA is ‪255.81 M‬ USD, and current EBITDA margin is 58.88%. See more stats in Protagonist Therapeutics, Inc. financial statements.
Like other stocks, PTGX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Protagonist Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Protagonist Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Protagonist Therapeutics, Inc. stock shows the strong buy signal. See more of Protagonist Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.